Methods: A total of 22 hepatitis B e antigen (HBeAg)-positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine (3TC) and adefovir disoproxil (ADV) therapy were treated with 1.0 mg of ETV. Clinical and virological parameters were monitored every 3 months. Restriction fragment mass polymorphism assays were used to detect antiviral resistance. Results: During 3TC and ADV therapy, 11 patients had rtM204V/I mutations, 2 had rtA181V/T or rtN236T, 7 had both and 2 had no 3TC-or ADV-related mutations. After switching to ETV monotherapy, the median change in serum hepatitis B virus (HBV) DNA level was -2.1 log 10 copies/ml. Virological response (HBV DNA<300 copies/ml) was achieved in 1 of 18 patients with pre-existing rt204 mutations, whereas it was achieved in all 4 patients without pre-existing rt204 mutations regardless of the presence of rt181 or rt236 mutations. Changes in mutational patterns during ETV therapy showed that rt204 mutations persisted or re-emerged. Relative abundances of rtM204V/I mutations in total viral populations gradually increased under ETV rescue, whereas those with rtA181V/T and rtN236T mutations decreased. ETV resistance mutations (rtL180M+rtT184I/L[rtS202G]+rtM204V) were detected in five patients with pre-existing rt204 mutations. Conclusions: ETV monotherapy resulted in a limited virological response in patients who had previously failed 3TC and ADV rescue therapy. The limited efficacy might be associated with residual or reselected rtM204V/I mutations leading to ETV resistance. Combination treatment including potent antiviral agents should be recommended for patients with pre-existing rtM204V/I mutations.
Background: The efficacy of entecavir (ETV) monotherapy in treatment-experienced patients with chronic hepatitis B (CHB) is debatable.
Methods: A total of 22 hepatitis B e antigen (HBeAg)-positive CHB patients who had shown viral breakthrough or suboptimal response with lamivudine (3TC) and adefovir disoproxil (ADV) therapy were treated with 1.0 mg of ETV. Clinical and virological parameters were monitored every 3 months. Restriction fragment mass polymorphism assays were used to detect antiviral resistance. Results: During 3TC and ADV therapy, 11 patients had rtM204V/I mutations, 2 had rtA181V/T or rtN236T, 7 had both and 2 had no 3TC-or ADV-related mutations. After switching to ETV monotherapy, the median change in serum hepatitis B virus (HBV) DNA level was -2.1 log 10 copies/ml. Virological response (HBV DNA<300 copies/ml) was achieved in 1 of 18 patients with pre-existing rt204 mutations, whereas it was achieved in all 4 patients without pre-existing rt204 mutations regardless of the presence of rt181 or rt236 mutations. Changes in mutational patterns during ETV therapy showed that rt204 mutations persisted or re-emerged. Relative abundances of rtM204V/I mutations in total viral populations gradually increased under ETV rescue, whereas those with rtA181V/T and rtN236T mutations decreased. ETV resistance mutations (rtL180M+rtT184I/L[rtS202G]+rtM204V) were detected in five patients with pre-existing rt204 mutations. Conclusions: ETV monotherapy resulted in a limited virological response in patients who had previously failed 3TC and ADV rescue therapy. The limited efficacy might be associated with residual or reselected rtM204V/I mutations leading to ETV resistance. Combination treatment including potent antiviral agents should be recommended for patients with pre-existing rtM204V/I mutations.
Hepatitis B virus (HBV) replication has a key role in the disease progression and development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients [1] [2] [3] ; therefore, the major goal of anti-HBV therapy is the sustained suppression of HBV replication without the emergence of drug resistance mutations and the prevention of hepatic decompensation and HCC [4] .
Lamivudine (3TC) was the first oral agent approved for the treatment of CHB patients and was initially successful in suppressing HBV DNA [5] ; however, the wide use of 3TC monotherapy during the past 10 years has led to a progressive increase in the number of patients with 3TC resistance because of its poor resistance profile [6] . Adefovir dipivoxil (ADV) was the second oral anti-HBV agent approved for first-line therapy or rescue therapy for 3TC resistance; however, long-term treatment with ADV has led to the emergence of ADV resistance [7] . Moreover, a higher rate of ADV resistance has been reported in patients with pre-existing 3TC-resistant mutations compared with treatment-Introduction naive patients, especially in those treated with ADV monotherapy [8] . Recently, there has been increasing evidence indicating that the addition of ADV to continued 3TC therapy is associated with a lower rate of emergence of ADV resistance [9, 10] , but does not result in significantly improved viral suppression [9] .
Entecavir (ETV) is a recently approved oral agent for treatment-naive or treatment-experienced CHB patients. ETV has an excellent potency and a high genetic barrier to resistance in treatment-naive patients [11, 12] . The high genetic barrier to resistance is attributable to the requirement for three amino acid substitution mutations for resistance to occur, including two of the mutations associated with 3TC resistance (M204V/I and L180M) plus an additional ETV-associated mutation at codons rt169, rt184, rt202 or rt250 [13] . Despite the great efficacy of ETV in treatment-naive patients, there is controversy about the antiviral efficacy of ETV in treatment-experienced CHB patients [14] [15] [16] [17] [18] .
The aim of this study was to evaluate the antiviral efficacy of ETV in patients who had failed to achieve viral response during 3TC and ADV rescue therapy. We also investigated the evolution of antiviral resistance mutations and the emergence of HBV mutations associated with ETV resistance during ETV monotherapy by using restriction fragment mass polymorphism (RFMP) assays.
Methods

Patients
Between September 2006 and September 2007, 22 CHB patients who had viral breakthrough or a suboptimal response to 3TC and ADV rescue therapy were included. The patients were treated with ETV monotherapy at a daily dose of 1.0 mg for ≥12 months. There was no time gap when the drugs were switched. They were followed-up every 3 months during ETV monotherapy for clinical assessments of tolerability, physical examination and blood sampling to measure laboratory parameters and HBV status. Serum HBV DNA levels were assessed using the COBAS Amplicor PCR assay (Roche Molecular Systems, Branchburg, NJ, USA) with a lower limit of detection of 300 (2.5 log 10 ) copies/ml. This study was approved by the Institutional Review Board of the Konkuk University Hospital (Seoul, South Korea).
Definitions
Virological response was defined as a decrease in serum HBV DNA to an undetectable level (<2.5 log 10 copies/ml) by PCR assay [19] . Viral breakthrough was defined as a ≥1 log 10 copies/ml increase in HBV DNA from nadir after an initial decrease in HBV DNA by >2 log 10 copies/ml [19] . Suboptimal response was arbitrarily defined as HBV DNA>4 log 10 copies/ml after ≥6 months of antiviral therapy [20] .
Detection of antiviral-resistant mutations
Serial samples were collected from each patient at the time of initiation of each antiviral agent, once every 3 months during treatment and at the time of viral breakthrough, and they were stored frozen at -80°C. For surveillance of HBV antiviral resistance mutations, the serum samples taken at baseline and at the time of viral breakthrough or suboptimal response to the prior 3TC or ADV treatment were tested. After switch to ETV monotherapy, mutational analysis of HBV polymerase in each patient was performed using the individual serial samples at 3-month intervals.
Analysis of the mutations associated with 3TC (rt180 and rt204) or ADV (rt181 and rt236) were performed with a matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MS)-based genotyping assay, termed RFMP, as previously described [21] [22] [23] [24] . The RFMP assay system had a low detection limit of 2.5 log 10 copies/ml of HBV DNA in serum [21] and could detect antiviral resistance mutations that constituted as little as 1% of the total viral population [19, 22] . In addition, its feasible range for measuring relative abundance ratio of mutant versus wild-type virus was from 5% to 95% when the total viral load was ≥4 log 10 copies/ml [23] . The predominance of mutations was arbitrarily defined as a twofold or greater increase of antiviral resistance mutants than wild type in this study.
RFMP analysis of mutations associated with ETV resistance was established with following primer pairs:
5′-GGATGCCTGGGCTTTCGCAAG-3′ (nucleotides 618-633) and 5′-GGATGCACTCCCA TAGG-3′ (nucleotides 637-648) for codon rt169, 5′-GGATGTCCTGGCTCAGTTT-3′
(nucleotides 664-678) and 5′-GGATGACAAATGGCACT-3′ (nucleotides 682-693) for codon rt184, 5′-GGATG TGTTTGGCTTTC-3′ (nucleotides 721-732) and 5′-TTGGCCCCCAGGATG TACCACATGATC-3′ (nucleotides 742-764) for codon rt202, 5′-GGATGT GTTTGGCTTTCAGTTAT-3′ (nucleotides 721-738) and 5′-TTGGCCCCCAGGATGTACC ACATGATC-3′ (nucleotides 742-764) for codon rt204, and 5′-GGATGTCCCTTAACTTC-3′ (nucleotide 865-876) and 5′-GGATGAGCTTCCAATTACATATCC-3′ (nucleotides 880-898) for codon rt250. The underlined sequence in each primer introduced new FokI sites into the PCR products. The presence of mutations was analysed by MS of the 9-mer, 10-mer, 7-mer, 11-mer and 12-mer fragments for rtI169T, rtS202G, rtT184S, rtM204V and rtM250V, respectively, followed by comparison to expected mass patterns summarized in Additional file 1. The RFMP assay results were validated by 100% concordance with those obtained by repetitive direct sequencing. Analytical sensitivities were estimated to be 2.5 log 10 copies/ml and lower limits of detection for minority viral populations of RFMP in detecting the ETV-resistant strains was 1% and was similar to those obtained in 3TC-or ADV-resistance-related mutant strains [21, 22] .
Statistical analyses
Results are reported as median (range). HBV DNA levels were logarithmically transformed for analysis. Continuous variables were compared with the twotailed Student's t-test and categorical variables with the two-tailed χ 2 test or Fisher's exact test. P-values <0.05 were considered as statistically significant.
Results
Patient characteristics prior to ETV monotherapy
Baseline characteristics of patients prior to ETV monotherapy are summarized in Table 1 . A total of 22 patients were included. All patients were hepatitis B e antigen (HBeAg)-positive and negative for hepatitis B e antibodies. None of the patients were coinfected with HIV or hepatitis C virus. The patients had compensated liver disease and seven of them had liver cirrhosis. All patients had been treated with 3TC (100 mg/day) as the first-line therapy for a median of 15 months. During 3TC monotherapy, they experienced viral breakthrough or a suboptimal response to 3TC, and 18 patients among them were confirmed to have rtM204V/I mutations. After viral breakthrough or suboptimal response to 3TC, 3TC was switched to ADV (10 mg/day); 12 patients were treated with ADV monotherapy and 10 patients were treated by adding on ADV while continuing 3TC. During ADV rescue therapy, all patients experienced viral breakthrough or a suboptimal response. Of the 10 patients who experienced viral breakthrough during ADV therapy, 6 were confirmed to have rtA181V/T and/or rtN236T mutations. Of the 12 patients who were suboptimal responders to ADV, 3 were confirmed to have rtA181V/T mutations.
Antiviral responses to ETV monotherapy
At the start of ETV rescue therapy, the median HBV DNA level was 6.8 log 10 copies/ml (range 5.9-8.0). The median decreases of HBV DNA level were -1.6 and -2.0 log 10 copies/ml at 3 and 6 months of ETV therapy, respectively. At the end of the observation period (median 13.5 months), the median decrease of HBV DNA level was -2.1 log 10 copies/ml. Virological response was achieved in 5 (23%) patients after a median duration of 9.0 months (range 6.0-12.0) of ETV treatment. In the remaining 17 patients, 13 patients were suboptimal responders to ETV and 2 patients experienced viral breakthrough. All four patients without pre-existing rtM204V/I mutations (regardless of the presence or absence of pre-existing rtA181V/T or rtN236T mutations) achieved virological response to ETV rescue, whereas only 1 of 18 patients with pre-existing rtM204V/I mutations achieved virological response. The mean reduction in HBV DNA was significantly lower in patients with pre-existing rtM204V/I mutations compared with patients without rtM204V/I mutations at ETV treatment months 3, 6, 9 and 12, respectively ( Figure 1 ). Univariate analyses showed that virological response was only significantly associated with an absence of pre-existing rtM204V/I mutations (P<0.01) among clinical and virological parameters, such as age, sex, liver cirrhosis, pre-existing 3TC-or ADV-resistant mutations, HBV DNA or alanine aminotransferase (ALT) levels at the start of ETV therapy and treatment duration. At the start of ETV rescue therapy, the median ALT level was 62 IU/l (range 36-408) and 20 of 22 patients had an ALT level above the upper limit of normal (ULN; 40 IU/l). ALT normalization was achieved in 11 of 20 (55%) patients during ETV monotherapy and HBeAg seroconversion occurred in one patient. Treatment outcomes of the patients during ETV therapy are summarized in Table 2 .
Mutational analysis during ETV treatment
At the initiation of ETV rescue therapy, rtM204V/I mutations were detected in 10 patients and A181V/T and/or N236T mutations were detected in 8 patients. One patient had both 3TC-resistant and ADV-resistant mutations, and three patients had wild type at multiple sites of HBV mutations associated with antiviral resistance. During ETV rescue therapy, M204V/I mutations re-emerged or persisted, and their relative abundances in total viral populations gradually increased in the 15 of 18 patients with pre-existing 3TC-resistant mutations (Table 3 ). In five of those patients, ETV-resistant mutations (rtL180M+rtT184L/I+rtM204V in two patients and rtL180M+rtS202G+rtM204V in three patients) were detected at a median of 12 months of ETV therapy (range 9-18 months; Figure 2 ), and 2 of 5 patients with ETV resistance mutations experienced viral breakthrough (patients 5 and 13). Representative RFMP analyses of mutations associated with ETV resistance in patient 9 and patient 13 are shown in Figure 3 . Mutations at codons rt169 or rt250 were not detected in any patients. Changes in mutational patterns demonstrated that the relative abundances of ADVresistant mutations in total viral populations decreased under ETV rescue; however, 3 of 9 patients (patients 15, 16 and 18) still had ADV-resistant mutations at the last follow-up period (Table 3) .
Discussion
This study demonstrated that ETV monotherapy is not effective in patients who failed 3TC and ADV as a rescue treatment, especially in patients with pre-existing rtM204V/I mutations. We observed that pre-existing M204V/I mutations persisted or re-emerged during ETV rescue therapy in those patients.
ETV exhibits potent activity against HBV and the occurrence of ETV resistance mutations is extremely low [25, 26] , with a cumulative genotypic resistance rate of 1.2% at 5 years in treatment-naive patients [27] . However, antiviral efficacy of ETV against 3TC-resistant HBV is still unsatisfactory [14] [15] [16] . Clinical studies showed that ETV resulted in a limited virological response and ETV-resistant mutations emerged more frequently in 3TC-experienced patients compared with treatment-naive patients [6, 13] . Antiviral activity of ETV against ADV-resistant HBV is another controversial issue. Theoretically, rescue therapy with ETV was suggested to be beneficial for ADVresistant patients because of the different resistance profiles between ETV and ADV [6, 28] , and in vitro studies demonstrated that ADV-resistant mutations were susceptible to ETV [29, 30] . However, recent clinical reports have offered conflicting results regarding the efficacy of ETV in CHB patients with ADV resistance [17, 18] . Recently, Reijnders et al. [18] reported that ETV monotherapy dosed at 1 mg resulted in a limited virological response in patients with a persistently high level of viral replication during ADV treatment. However, in their study, 75% of the 3TC-and ADV- 
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Patients with pre-existing 3TC-r mutations (n=18) Figure 1 . Viral decreases according to the pre-existing lamivudine resistance mutation rtM204V/I ETV, entecavir; HBV, hepatitis B virus; 3TC, lamivudine; 3TC-r, lamivudine resistance.
Baseline variable Value
Median HBV DNA at initiation of ETV, log 10 copies/ml (range) 6.8 (5.9-8.0) Median duration of ETV, months (range) 13.5 (12.0-18.0) Median HBV DNA decrease at 6 months, log 10 copies/ml (range) -2.0 (0.1--4.6) Median HBV DNA decrease at last follow-up, log 10 copies/ml (range) -2.1 (1.4--4.9) Virological response to ETV, n (%) 5 (23) HBeAg seroconversion or loss of HBeAg, n (%) 1 (5) The relative abundances were not applicable (NA) because total viral loads were <4 log 10 copies/ml in samples at 6 months after entecavir (ETV) treatment. experienced patients had previously developed 3TC resistance; therefore, it is difficult to suggest that prior experience of ADV therapy or ADV resistance mutations might have affected the limited overall efficacy of ETV in those patients. In this study, 22 patients who experienced viral breakthrough or suboptimal response during 3TC and ADV as a rescue therapy were treated with ETV monotherapy sequentially. Of these 22 patients, 18 (82%) patients had previously developed 3TC resistance, 15 (68%) had showed suboptimal responses to ETV and 2 (9%) patients experienced viral breakthrough during a median observation of 13.5 months with ETV monotherapy. Also, ETV-resistant mutations were detected in 5 (23%) patients at a median of 12 months of ETV therapy, and it appeared earlier and more frequently than was reported in previous studies on treatmentnaive patients or 3TC refractory patients [11, 14] . The limited efficacy of ETV might be related to preexisting 3TC-resistant mutations. Our data showed that only 1 of the 18 patients with pre-existing 3TC-resistant mutations achieved virological response and the presence of pre-existing 3TC-resistant mutation significantly reduced the virological response. Mutational analyses also demonstrated that 3TC-resistant mutations re-emerged or persisted and their relative abundances in total viral populations gradually increased under ETV monotherapy in most patients with pre-existing 3TC-resistant mutations. In addition, ETV-resistant mutations occurred among these patients. These results also suggest that pre-existing 3TC-resistant mutations could continue to be selected by ETV therapy. If we compare the five patients who had ETV-resistant mutations in Figure 2 , their HBV DNA levels decreased transiently under ETV therapy, only when a proportion of wild-type at codon rtM204 was present at the start of ETV therapy. Subsequently, the response to ETV was blunted and remained relatively flat when the transition to M204V/I mutations predominance took place for several months; thus, allowing the selection of the additional ETV-resistant substitutions required to overcome drug suppression and resulting in a viral breakthrough. This trend of association of evolution of M204V/I mutations with 
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clinical response to ETV is consistent with a previous in vitro study [31] indicating that M204V/I mutations exhibited a higher relative level of phenotypic resistance to ETV; therefore, ETV monotherapy does not seem to be a good choice as a rescue for treatment of patients with pre-existing 3TC-resistant mutations. By contrast, ETV still has some importance in treatment-experienced patients, especially in suboptimal responders to 3TC or ADV without antiviralresistant mutations. In this study, all four patients who had not experienced 3TC-resistant mutations achieved virological response regardless of the presence or absence of pre-existing ADV-resistant mutations. Changes in mutational patterns under ETV therapy also demonstrated that the relative abundances of ADV-resistant mutations were slowly decreased; however, ADV-resistant mutations still remained in three of nine patients at the last follow-up. Although N236T and A181V/T mutants are susceptible to ETV in vitro, the potential presence of cross-resistance or other compensatory mutations in HBV polymerase might contribute to the persistence of ADV-resistant mutants. Further investigations are needed to clarify the persistence of ADV-resistant mutation during ETV monotherapy.
Approval of multiple nucleoside/nucleotide analogues to clinical practice and their sequential or combinational use increase the chance of selection of HBV variants with complex mutational patterns; thus, there is a need to simultaneously analyse several mutational hotspots associated with antiviral resistance and for optimal management of CHB. In this study, we introduced an advanced RFMP-based assay that exploited differential lengths of oligonucleotides (7-12-mer) depending upon each codon associated with ETV resistance, which would not necessitate repetitive PCR and MS analyses for multiple mutations. The RFMP method sensitively and reproducibly detected known point mutations of amino acids in the reverse transcriptase domains of HBV polymerase. Analytical sensitivity and a lower limit of detection for the minority mutant population as low as 2.5 log 10 copies/ml and 1% of RFMP assays for ETV mutation should enable early detection of treatment failure, subsequent intervention and prevention of drug resistance as it develops [21, 22] . However, there is a possibility that mutations in other codons that were not covered by the RFMP assay might contribute to the individualized drug response to a certain extent during sequential treatment; therefore, clonal identification of HBV quasispecies during longitudinal sampling and subsequent in vitro susceptibility testing of potential variants with or without known primary mutations against antiviral agents should be supplemented to elucidate the viral evolution and acquisition of multiple antiviral drug resistance mutations.
Our patients were treated with 3TC as the first-line anti-HBV treatment and ADV as a rescue therapy. Recent guidelines for treatment of CHB patients no longer recommend 3TC as a first-line agent or sequential monotherapy [32, 33] . In many Asian countries with HBV endemic areas, including Korea, many patients have already been treated with 3TC and ADV sequential therapy because of a relatively low cost and the drug-by-drug approval process of anti-HBV agents. However, the effective rescue therapy for patients who have suffered from treatment failure with the sequential therapy is still controversial. This study clearly demonstrated that ETV is not an ideal option for the rescue therapy for those who failed sequential treatment with 3TC and ADV. Recent guidelines recommend tenofovir disoproxil fumarate (TDF)-based therapy with or without a combination of nucleoside/ nucleotide analogues as a rescue for the treatment of these patients [32, 33] . We have reported that TDF and 3TC combination markedly suppressed HBV replication in ADV-resistant patients with pre-existing 3TC resistance [34] . Combination treatment that includes TDF could be a useful therapeutic option for patients with 3TC and/or ADV resistance
In conclusion, ETV monotherapy showed a limited antiviral efficacy in CHB patients who had previously failed 3TC and ADV rescue therapy. The suboptimal response to ETV rescue therapy could predispose HBV to emergence of ETV resistance mutations. The limited efficacy of ETV in those patients might be primarily related to persistence or reselection of pre-existing 3TC-resistant mutations. Sequential monotherapy with an anti-HBV agent should be avoided to prevent emergence of multidrug resistance of HBV. Further investigations for efficacy of ETV combined with potent antiviral agents are needed to provide the therapeutic strategies for antiviral-resistant patients.
